Browse our latest Cancer Biology articles

The archetypal tumor promoter PMA, which promotes cancer without mutating the DNA, increases Wnt signaling by activating macropinocytosis and membrane trafficking in Xenopus embryos and tumor cells.

Loss of membrane-bound ICAM-1, overexpression of soluble ICAM-1 or ILKAP activity in tumor cells induce resistance to antigen-specific cytotoxic T-cell-mediated killing independently from regulating antigen presentation, PD-L1 expression, IFN-γ, or TNF-α responsiveness.

Morphological profiling of untreated HCT116 cells using Cell Painting reveals a signature of bortezomib resistance, providing a proof-of-concept for the unbiased analysis of drug resistance.

A new type of mRNAs-loaded CD133⁺ vesicles, named intercellsome, mediate cell-cell communications to compensate intracellular proliferative signal deficit, representing a previously unrecognized mechanism of cell proliferation under stress.

SPOT-MAS (screening for the presence of tumor by methylation and size) is an affordable and effective multi-cancer early detection test analyzing multiple features of circulating tumor DNA.

TNFAIP2 was found to interact with IQGAP1 and Integrin β4, which activates RAC1 through TNFAIP2 and IQGAP1 and confers DNA damage-related drug resistance in triple-negative breast cancer.

Experimental and clinical models identify an effective add-on therapy for drug resistant estrogen receptor positive advanced breast cancer.

FOXP2, encoding a forkhead-box transcription factor regarded as vital to proper development of human speech, was revealed to have an oncogenic potential and activate MET signaling in prostate cancer.

The inhibition of EPAC1, a cAMP-binding protein, appears as a potential therapeutic strategy to limit doxorubicin-induced cardiotoxicity without interfering with its antitumoral activity.